Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

摘要: Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists plan long-term therapy patients. However, many currently available front-line salvage agents used advanced are associated cumulative and/or irreversible toxicities that pose challenges planning. The effects some these therapies may render patients less tolerant subsequent treatments lead cycle diminishing treatment options each remission relapse. Additionally, potential experience toxicity must be carefully weighed against goals prolonging disease-free interval improving patient quality life. A number armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, topotecan), many, but not all which toxicity. For instance, neurotoxicity cisplatin first-line diminish option retreatment platinum at first In contrast, main topotecan is noncumulative, manageable myelosuppression. this review, major predominant chemotherapy discussed along selected management approaches context planning sequencing.